Literature DB >> 15077701

Motor impairments, neurological signs, and developmental level in individuals with Angelman syndrome.

Eva Beckung1, Suzanne Steffenburg, Mårten Kyllerman.   

Abstract

The aim of this study was to examine the character of motor dysfunction in individuals with Angelman syndrome (AS). Thirty-three children and adolescents (median age 6 years, range 18 months to 23 years) were consecutively investigated for learning disability, epilepsy, and motor dysfunction to detect suspected AS. Twenty-three individuals (13 males, 10 females; median age 5 years 6 months, range 21 months to 23 years) fulfilled international consensus criteria for AS. Clinical diagnosis was supported by a positive DNA methylation test in eleven participants. Ten participants (seven males, three females; median age six years, range 18 months to 13 years) did not comply with consensus criteria for AS and were regarded as a comparison group. There was no significant difference between the AS and the comparison group regarding age or developmental level. Median developmental quotient level was 26 months (range 8 to 63 months); median gross motor developmental level in participants with AS was 24 months (range 8 to 60 months); median fine motor developmental level was 15 months (range 6 to 60 months). Muscle strength, spasticity, tremor, and coactivation were assessed: distal lower limb spasticity, ataxic like gait, stiff lower limbs, and the presence of coactivation during locomotion were significantly more frequent in participants with AS than in the comparison group (p<0.05). Asymmetry of muscle strength and spasticity were frequent. Neurological abnormalities were insufficient for a diagnosis of cerebral palsy and impeded function less than immaturity in both AS groups. Risk of increasing impairment needs to be anticipated to prevent negative long-term effects of muscle imbalance and motor asymmetries in individuals with AS.

Entities:  

Mesh:

Year:  2004        PMID: 15077701     DOI: 10.1017/s0012162204000398

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  8 in total

1.  Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome.

Authors:  Richard M Gustin; Terry Jo Bichell; Michael Bubser; Jennifer Daily; Irina Filonova; Davit Mrelashvili; Ariel Y Deutch; Roger J Colbran; Edwin J Weeber; Kevin F Haas
Journal:  Neurobiol Dis       Date:  2010-04-25       Impact factor: 5.996

2.  Do the physiotherapy results make us happy in a case with 'happy puppet' (Angelman) syndrome?

Authors:  Ozgun Kaya Kara; Akmer Mutlu; Mintaze Kerem Gunel; Goknur Haliloglu
Journal:  BMJ Case Rep       Date:  2010-12-29

3.  Spastic Diplegia in a Haitian Girl with Angelman Syndrome.

Authors:  Kumarie Latchman; Margarita Nieto-Moreno; Roberto Lopez Alberola
Journal:  J Pediatr Genet       Date:  2019-09-23

4.  Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3A isoform.

Authors:  Anjali Sadhwani; Neville E Sanjana; Jennifer M Willen; Stephen N Calculator; Emily D Black; Lora J H Bean; Hong Li; Wen-Hann Tan
Journal:  Am J Med Genet A       Date:  2018-05-07       Impact factor: 2.802

Review 5.  Unmet clinical needs and burden in Angelman syndrome: a review of the literature.

Authors:  Anne C Wheeler; Patricia Sacco; Raquel Cabo
Journal:  Orphanet J Rare Dis       Date:  2017-10-16       Impact factor: 4.123

6.  Strabismus surgery in Angelman syndrome: More than ocular alignment.

Authors:  Paola Michieletto; Stefano Pensiero; Laura Diplotti; Luca Ronfani; Manuela Giangreco; Alberto Danieli; Paolo Bonanni
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

Review 7.  A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome.

Authors:  Jessica Duis; Mark Nespeca; Jane Summers; Lynne Bird; Karen G C B Bindels-de Heus; M J Valstar; Marie-Claire Y de Wit; C Navis; Maartje Ten Hooven-Radstaake; Bianca M van Iperen-Kolk; Susan Ernst; Melina Dendrinos; Terry Katz; Gloria Diaz-Medina; Akshat Katyayan; Srishti Nangia; Ronald Thibert; Daniel Glaze; Christopher Keary; Karine Pelc; Nicole Simon; Anjali Sadhwani; Helen Heussler; Anne Wheeler; Caroline Woeber; Margaret DeRamus; Amy Thomas; Emily Kertcher; Lauren DeValk; Kristen Kalemeris; Kara Arps; Carol Baym; Nicole Harris; John P Gorham; Brenda L Bohnsack; Reid C Chambers; Sarah Harris; Henry G Chambers; Katherine Okoniewski; Elizabeth R Jalazo; Allyson Berent; Carlos A Bacino; Charles Williams; Anne Anderson
Journal:  Mol Genet Genomic Med       Date:  2022-02-11       Impact factor: 2.183

8.  Movement Disorders and Syndromic Autism: A Systematic Review.

Authors:  L Bell; A Wittkowski; D J Hare
Journal:  J Autism Dev Disord       Date:  2019-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.